Additive effect of PTH (1-34) and zoledronate in the prevention of disuse osteopenia in rats

Bone. 2014 Sep:66:287-95. doi: 10.1016/j.bone.2014.06.020. Epub 2014 Jun 24.

Abstract

Immobilization is known to cause a rapid bone loss due to increased osteoclastic bone resorption and decreased osteoblastic bone formation. Zoledronate (Zln) is a potent anti-resorptive pharmaceutical, while intermittent PTH is a potent bone anabolic agent. The aim of the present study was to investigate whether PTH or Zln alone or in combination could prevent immobilization-induced osteopenia. Immobilization was achieved by injecting 4IU Botox (BTX) into the right hind limb musculature. Seventy-two 16-week-old female Wistar rats were randomized into 6 groups; baseline (Base), control (Ctrl), BTX, BTX+PTH, BTX+Zln, and BTX+PTH+Zln. PTH (1-34) (80μg/kg) was given 5days/week and Zln (100μg/kg) was given once at study start. The animals were killed after 4weeks of treatment. The bone properties were evaluated using DEXA, μCT, dynamic bone histomorphometry, and mechanical testing. BTX resulted in lower femoral trabecular bone volume fraction (BV/TV) (-25%, p<0.05), lower tibial trabecular bone formation rate (BFR/BS) (-29%, p<0.05), and lower bone strength (Fmax) at the distal femur (-19%, p<0.001) compared with Ctrl. BTX+PTH resulted in higher femoral BV/TV (+31%, p<0.05), higher tibial trabecular BFR/BS (+297%, p<0.05), and higher Fmax at the distal femur (+11%, p<0.05) compared with BTX. BTX+Zln resulted in higher femoral BV/TV (+36%, p<0.05), lower tibial trabecular BFR/BS (-93%, p<0.05), and higher Fmax at the distal femur (+10%, p<0.05) compared with BTX. BTX+PTH+Zln resulted in higher femoral BV/TV (+70%, p<0.001), higher tibial trabecular BFR/BS (+59%, p<0.05), and higher Fmax at the distal femur (+32%, p<0.001) compared with BTX. In conclusion, BTX-induced immobilization led to lower BV/TV, BFR/BS, and Fmax. In general, PTH or Zln alone prevented the BTX-induced osteopenia, whereas PTH and Zln given in combination not only prevented, but also increased BV/TV and BFR/BS, and maintained Fmax at the distal femoral metaphysis compared with Ctrl.

Keywords: Biomechanics; Bisphosphonate; Histomorphometry; Immobilization; MicroCT; PTH.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Absorptiometry, Photon
  • Animals
  • Biomechanical Phenomena
  • Bone Diseases, Metabolic / diagnostic imaging
  • Bone Diseases, Metabolic / drug therapy*
  • Bone Diseases, Metabolic / physiopathology
  • Bone Diseases, Metabolic / prevention & control*
  • Bone and Bones / diagnostic imaging
  • Bone and Bones / drug effects
  • Bone and Bones / pathology
  • Bone and Bones / physiopathology
  • Diphosphonates / pharmacology
  • Diphosphonates / therapeutic use*
  • Drug Synergism
  • Female
  • Imaging, Three-Dimensional
  • Imidazoles / pharmacology
  • Imidazoles / therapeutic use*
  • Muscular Disorders, Atrophic / diagnostic imaging
  • Muscular Disorders, Atrophic / drug therapy*
  • Muscular Disorders, Atrophic / physiopathology
  • Muscular Disorders, Atrophic / prevention & control*
  • Parathyroid Hormone / pharmacology
  • Parathyroid Hormone / therapeutic use*
  • Rats, Wistar
  • X-Ray Microtomography
  • Zoledronic Acid

Substances

  • Diphosphonates
  • Imidazoles
  • Parathyroid Hormone
  • Zoledronic Acid